Literature DB >> 21107629

Reversible occlusion (on-off) valves in shunted tumor patients.

Daniel N Hertle1, Johannes Tilgner, Karin Fruh, Timo Keinert, Anna M Hagenston, Andreas W Unterberg, Alfred Aschoff.   

Abstract

The first commercially produced adjustable valve for shunted hydrocephalus patients was introduced by H. Portnoy and R. Schulte in 1973. This valve is still in use and known as reversible occlusion or on-off valve. The reversible occlusion valve is mainly used in conjunction with an existing shunt in patients receiving intraventricular cytostatic therapy. The valve has a simple mechanical lock that is closed by external pressure application with a single finger. The study method is a retrospective clinical series of 15 patients undergoing a total of 16 valve implantations between 2003 and 2010 was carried out, and the valve was tested in vitro. We report a high incidence of accidental occlusions leading to a loss of consciousness in five patients (33.3%). We furthermore demonstrate in vitro that accidental occlusions can occur. The reversible occlusion valve is needed in shunted tumor patients receiving intrathecal administration of cytostatica. The mechanism works as long as no external pressure compresses the valve. However, head positions pose significant risks for unintentional occlusions. We stress the importance of: (1) a position near the midline avoiding the retroauricular or occipital regions, (2) a handling training for nurses and doctors, (3) instruction of patients and relatives, and (4) removal of the device after intrathecal cytostatic treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21107629     DOI: 10.1007/s10143-010-0297-y

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  10 in total

1.  [Efficiency of the on-off valve in the cerebrospinal fluid shunt (author's transl)].

Authors:  S Yamasaki; H Sato; J Kitamura; A Hirayama; K Osaka
Journal:  Nihon Geka Hokan       Date:  1976-01-01

2.  Malfunction of multipurpose valve shunt.

Authors:  A M Gerber
Journal:  J Neurosurg       Date:  1977-11       Impact factor: 5.115

3.  Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.

Authors:  M J Glantz; S LaFollette; K A Jaeckle; W Shapiro; L Swinnen; J R Rozental; S Phuphanich; L R Rogers; J C Gutheil; T Batchelor; D Lyter; M Chamberlain; B L Maria; C Schiffer; R Bashir; D Thomas; W Cowens; S B Howell
Journal:  J Clin Oncol       Date:  1999-10       Impact factor: 44.544

4.  AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective.

Authors:  Christian Hoffmann; Eva Wolf; Christoph Wyen; Gerd Fätkenheuer; Jan Van Lunzen; Hans-Juergen Stellbrink; Albrecht Stoehr; Andreas Plettenberg; Hans Jaeger; Richard Noppeney; Marcus Hentrich; Nicola Goekbuget; Dieter Hoelzer; Heinz-August Horst
Journal:  Leuk Lymphoma       Date:  2006-09

5.  Anti-siphon and reversible occlusion valves for shunting in hydrocephalus and preventing post-shunt subdural hematomas.

Authors:  H D Portnoy; R R Schulte; J L Fox; P D Croissant; L Tripp
Journal:  J Neurosurg       Date:  1973-06       Impact factor: 5.115

6.  Systemic high-dose methotrexate plus ifosfamide is highly effective for central nervous system (CNS) involvement of lymphoma.

Authors:  Lars Fischer; Agnieszka Korfel; Philipp Kiewe; Martin Neumann; Kristoph Jahnke; Eckhard Thiel
Journal:  Ann Hematol       Date:  2008-08-05       Impact factor: 3.673

7.  Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report.

Authors:  Hans-Joachim Stemmler; Karin Mengele; Manfred Schmitt; Nadia Harbeck; Dorit Laessig; Karin A Herrmann; Pamela Schaffer; Volker Heinemann
Journal:  Anticancer Drugs       Date:  2008-09       Impact factor: 2.248

8.  Prognostic factors and outcomes in patients with leptomeningeal melanomatosis.

Authors:  Laura Harstad; Kenneth R Hess; Morris D Groves
Journal:  Neuro Oncol       Date:  2008-08-14       Impact factor: 12.300

9.  A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies.

Authors:  Morris D Groves; Michael J Glantz; Marc C Chamberlain; Karen E Baumgartner; Charles A Conrad; Sigmund Hsu; Jeffrey S Wefel; Mark R Gilbert; Sandra Ictech; Kathy U Hunter; Arthur D Forman; Vinay K Puduvalli; Howard Colman; Kenneth R Hess; W K Alfred Yung
Journal:  Neuro Oncol       Date:  2008-03-03       Impact factor: 12.300

10.  Breast cancer leptomeningeal metastasis--the role of multimodality treatment.

Authors:  Halina Rudnicka; Anna Niwińska; Magdalena Murawska
Journal:  J Neurooncol       Date:  2007-02-20       Impact factor: 4.506

  10 in total
  1 in total

1.  Shunt technology for infants and a lifetime.

Authors:  Víctor J Fernández Cornejo; Samer K Elbabaa
Journal:  Childs Nerv Syst       Date:  2021-07-08       Impact factor: 1.475

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.